<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="correction" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09169</article-id><article-id pub-id-type="doi">10.7554/eLife.09169</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Correction</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Correction: Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kandela</surname><given-names>Irawati</given-names></name><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Chou</surname><given-names>James</given-names></name><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Chow</surname><given-names>Kartoa</given-names></name><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes"><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>08</day><month>06</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>e09169</elocation-id><permissions><copyright-statement>© 2015, Kandela et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Kandela et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" id="ra1" related-article-type="corrected-article" xlink:href="10.7554/eLife.06959"/><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.3</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p>Kandela I, Chou J, Chow K, Reproducability Project: Cancer Biology. 2015. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. <italic>eLife</italic> <bold>4</bold>:e06959. doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7554/eLife.06959">10.7554/eLife.06959</ext-link></p><p>Published 22 May 2015</p></boxed-text><p>In the published Registered report there was an error in the iRDG peptide sequence listed in ‘Protocol 1: synthesis of iRDG’. The sequence was incorrectly listed as H-Gly-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-NH2. The correct sequence is: H-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-NH2.</p><p>This article has been corrected accordingly.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>RP:CB: We disclose that EI, FT, JL, and NP are employed by and hold shares in Science Exchange Inc. The experiments presented in this manuscript will be conducted by IK at the Developmental Therapeutics Core and JC at Lifetein, which are Science Exchange labs.</p></fn><fn fn-type="conflict" id="conf2"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></back></article>